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Allogeneic haematopoietic stem cell transplantation (HSCT) involves 
the transfusion of donor haematopoietic stem and progenitor 
cells (HSPC) procured from bone marrow, peripheral blood or 
the umbilical cord into a suitably primed recipient. Autologous 
haematopoietic stem cell transplantation, on the other hand, denotes 
the collection of the patient’s own stem cells prior to high-dose 
myeloablative chemotherapy, which are subsequently re-infused 
as a stem cell rescue to facilitate recovery of the marrow function. 
HSCT was pioneered by E D Thomas in 1957.[1] At that time, this 
procedure provided the first evidence that bone marrow had the 
capacity to regenerate the haematopoietic system and effectively 
treat or alleviate disorders of the same origin. Since 1957, HSCT has 
formed part of the treatment regimen of more than one million 
patients.[2] The European Group of Blood and Marrow Transplantation 
(EBMT) annually conducts a survey on HSCT activity in order to 
observe and monitor trends in Europe and affiliated countries. Data 
collected by these surveys provide evidence on the growing need 
for this procedure, with the number of HSCTs performed annually 
increasing from 4 234 in 1990 to over 40  000 in 2017.[3] There 
are no statistics currently available for the number of transplants 
performed in South Africa (SA), nor data reporting the need for this 
treatment or patient burden, and thus the deduction of an increased 
demand can be made on observed global trends. Schonfeld et al.[4] 
reported that 14  662 patients were diagnosed with haematological 
malignancies between 2000 and 2006, being responsible for 6% of 
the new cancer diagnoses and 8% of the cancer deaths reported in 
SA. These data were collected from the National Cancer Registry, 
which has certain caveats in that there may be underreporting of 
these cancers owing to diagnostic and reporting challenges in rural 
and lower socio-economic communities. A regional study conducted 
by Oelofse and Truter[5] found that haematological malignancies 
were not uncommon in Eastern Cape Province, and the incidence 
was comparable to some European populations. Additionally, certain 
black and Afrikaner population groups of SA are at greater risk of 
inheriting Fanconi’s anaemia owing to the genetic founder effect of 
the mutant Fanconi-associated genes.[6]
Indications for the procedure have expanded to encompass 
treatment of not only haematological and non-haematological 
malignancies, but also congenital and other acquired disorders of 
the haematopoietic system, as well as autoimmune and hereditary 
diseases (Table 1).[7]
Based on data collected from the World Health Organization 
(WHO)-defined global regions, Gratwohl et al.[2] reported that 58% 
of all HSCTs performed were autologous whilst 42% were allogeneic. 
Furthermore, the highest number of HSCTs were performed in 
Europe, followed by the Americas, Southeast Asia and the Western 
Pacific. The lowest number of HSCTs were performed in Eastern 
Mediterranean countries and Africa. Additionally, HSCTs were 
not carried out in countries with populations of less than 300 000 
or with a gross national income less than USD1 260 per capita.[2] 
These findings were attributed to the high costs associated with 
the procedure, limiting the availability of this treatment option in 
developing nations. These facts raise pertinent ethical questions 
regarding distributive justice, encompassing the limited access of 
lower socio-economic populations in sub-Saharan Africa to this 
treatment modality. This procedure is life-changing as it (i) counters 
the toxic effects of treatment regimens that are used to reduce 
tumour load; (ii) lengthens the time to relapse; or (iii) may potentially 
cure disorders (such as allogeneic HSCT for aplastic anaemia or 
acute myeloid leukaemia (AML)) that may otherwise prove fatal.
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In a single-centre study, Remberger et al.[8] reported a 70% 3-year 
overall survival rate in patients who received HSCT for a range of 
pathologies. Svenberg et al.[9] reported an overall survival rate of 82% 
for malignant and 96% for non-malignant disorders in paediatric 
patients 5 years after receiving the HSCT. As technology and skill 
have improved in the HSCT field, mortality rates have dropped 
from 82% between 1992 and 2000 to 46% by the end of 2009 as a 
composite for all eligible pathologies.[8]
Therapeutic success of the procedure depends on successful 
mobilisation of HSPCs from the marrow (either the patient’s marrow 
or a suitable donor), long-term and sustainable engraftment of the 
transplanted cells, and the prevention of graft-versus-host disease in 
the case of allogeneic HSCT.
Haematopoietic stem and progenitor 
cells
Embryonic haematopoiesis begins in the yolk sac and continues 
in the aorta-gonad-mesonephros region as well as at multiple 
other locations throughout gestation.[10] Adult haematopoiesis occurs 
predominantly in the bone marrow and may include extramedullary 
locations such as the liver and spleen.[11] HSPCs are multipotent 
cells responsible for the production and maintenance of all blood 
cell lineages.[12] These self-renewing cells firstly differentiate into 
common myeloid (CMP) and common lymphoid (CLP) progenitor 
cells (Fig. 1).[10] The adult HSPC niche (micro-environment that 
protects and sustains HSPC development, mobilisation and homing) 
is located in bone marrow along endosteal surfaces of trabecular 
bone in close proximity to endothelial cells. The latter allows for 
gaseous diffusion and nutrient movement between the intravascular 
compartment and the niche.[13]
Haematopoietic stem cell 
transplantation
The essential component of HSCT is the HSPCs which can be 
collected directly from bone marrow, peripheral blood through 
apheresis or umbilical cord blood.[14] Guidelines set out to identify 
and enumerate HSPCs were consolidated in 1996 by the International 
Society of Hematotherapy and Graft Engineering (ISHAGE),[15] 
recently renamed the International Society for Cell and Gene 
Therapy (ISCT). These guidelines remain the gold standard. HSPCs 
are identified and enumerated based on expression of the CD34 
surface protein and the dimly expressed common leukocyte antigen 
CD45.[15] HSPCs are also characterised by the absence of lineage-
specific markers.
The HSCT procedure may be divided into several stages, as 
illustrated in Fig. 2.[16] The fundamental principle behind HSCT 
in haematopoietic maligancy is the administration of HSPCs after 
myeloablative treatment, with the aim of having the donor stem 
cells home to their niche in the bone marrow to regenerate the 
haematopoietic system (stem cell rescue).
Disease-specific selection of patients 
for transplant and eligibility for 
transplant
HSCT is indicated as a primary treatment modality in patients 
diagnosed with various pathologies, or as second-line therapy when 
conventional protocols have failed or are ineffective (Table 1). Patient 
suitability is determined by several physiological and pathological 
factors (Table 2). These include cardiac, hepatic, pulmonary and 
renal function evaluations, viral and other infection screens, and 
the determination of the comorbidity index score.[17] Failure to meet 
these criteria may be seen as relative contraindications, as they may 
be superseded by expert opinion based on advances in medication, 
supportive care and technology.
HSCT is subject to identification of a suitable source for the 
acquisition of stem cells. In the case of autologous HSCT, a patient’s 
stem cells may not adequately mobilise into the peripheral circulation, 
yielding inadequate numbers to proceed with the protocol. Allogeneic 
HSCT may not be feasible if there are no available donors. The latter 
constitutes a particular challenge in the South African setting, and is 
highlighted later in this article.
Mobilisation
To facilitate harvesting, HSPCs are released from their marrow niche 
into the peripheral circulation by mobilisation. Mobilisation occurs 
when neutrophils, activated by granulocyte colony-stimulating 
Table 1. Pathologies in which either autologous and/or allogeneic HSCTs may be indicated
Disorder Autologous HSCT Allogeneic HSCT
Haematological malignancies Acute myeloid leukaemia Acute myeloid leukaemia and myelodysplastic syndrome
Multiple myeloma Primary myelofibrosis
Primary amyloidosis Chronic myeloid leukaemia
Acute lymphoblastic lymphoma Acute lymphoblastic leukaemia
Hodgkin’s lymphoma Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma Non-Hodgkin’s lymphoma
Other haematological disorders Aplastic anaemia
Paroxysmal nocturnal haemoglobinuria
Severe combined immunodeficiency
Autoimmune diseases Multiple sclerosis
Systemic lupus erythematosis
Crohn’s disease
Rheumatoid arthritis
Hereditary disorders Fanconi anaemia
Sickle cell anaemia
Thalassaemia major
Wiskott-Aldrich syndrome
Diamond-Blackfan anaemia
HSCT = haematopoietic stem cell transplantation.
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factors (G-CSF), release proteolytic enzymes 
such as elastase and cathepsin G. These 
enzymes cleave the terminal amino sequence 
of stromal cell-derived factor-1 (SDF-1) 
attached to the C-X-C chemokine receptor 
type 4 (CXCR-4) on HSPCs which tether 
the stem cells to their marrow niche.[18] 
G-CSF is the agent most frequently used for 
mobilisation as a single agent in allogeneic 
donors. Autologous stem cell collection 
requires that the patient concurrently 
receives a chemotherapeutic agent such 
as cyclophosphamide, as this augments 
the number of mobilised CD34+ cells.[19] 
Cyclophosphamide causes the release of 
proteases which cleave key adhesion molecules 
such as CXCR-4.[19] CD34+ counts within 
the peripheral circulation are determined 3 
hours prior to the first apheresis procedure. 
This is done either approximately 5 days 
after G-CSF for allogenic donors, or 14 days 
postmobilisation for patients who have been 
treated with G-CSF in combination with 
chemotherapy.[20] Mobilisation agents may 
also be used in combination with CXCR-4 
antagonists such as plerixafor (mozobil), 
if first-line regimens fail.[20] A minimum 
threshold in the pre-harvest blood of 2.5  × 
106 × CD34+ cells/kg predicts a satisfactory 
harvest yield.[21]
Factors influencing 
autologous 
haematopoietic stem 
and progenitor cell 
mobilisation
Factors which have been linked to poor 
HSPC mobilisation in autologous stem cell 
donors include advanced age, prior radiation 
and malignant infiltration. Exposure to 
purine analogues (fludarabine), alkylating 
agents (melphalan) and immunomodulators 
(lenalidomide) has also been associated 
with a negative prediction of mobilisation.[22] 
‘Proven’ poor mobilisers are characterised 
by circulating CD34+ cells peaking at less 
than 20 CD34+ cells/μL up to 6 days after 
mobilisation with G-CSF alone, up to 20 
days after G-CSF in combination with 
chemotherapy, or if there is a yield of less 
than 2.0 × 106 CD34+cells/kg collected with 
3 apheresis attempts.[23] ‘Predicted’ poor 
mobilisers have a history of previously failed 
collection attempts, have had prior treatment 
with chemotherapeutic or radiation regimens 
that affect HSPC mobilisation, and if any two 
of the following criteria are met: advanced 
disease treated with more than 2 lines of 
chemotherapy, refractory disease, extensive 
bone marrow infiltration, marrow cellularity 
less than 30% at the time of mobilisation, or 
age >65 years (Table 3).[23]
Factors influencing 
allogeneic donor 
suitability
Eligibility of donors largely depends on 
matching human leukocyte antigen (HLA) 
alleles, which are heterogeneous between 
individuals and races. Donors for allogeneic 
transplants may be sourced either from 
consenting family members (HLA-matched 
related donors if they have identical HLA 
alleles, or haploidentical if they have half-
matched HLA genotypes) or from unrelated 
HLA-matched donors (non-familial). 
Finding a suitable donor remains a challenge 
for many patients. The odds of finding an 
HLA-matched related donor is approximately 
1 in 4 and this depends on family size and 
structure. This drops significantly (as low 
as 1 in 100 000) when the search extends to 
HLA-matched unrelated donors. The HLA 
genes are located on chromosome 6 and 
are some of the most polymorphic genes 
in the human genome, resulting in large 
variability of expression.[24] Pertinently, the 
SA population is genetically highly diverse 
in respect to HLA alleles, particularly in people 
of African descent.[25] Although certain HLA 
Fig. 1. Schematic representation of haematopoiesis. Haematopoiesis is the process during which the 
various blood cells are produced and regenerated. Multipotent haematopoietic stem cells have the ability 
to self-regenerate and subsequently differentiate into two distinct cell lineages, myeloid and lymphoid. 
The common myeloid progenitor differentiates into platelet-forming megakaryocytes, erythrocytes, 
monocytes, neutrophils, eosinophils, basophils and mast cells. The common lymphoid progenitor 
differentiates into T- and B-lymphocytes and natural killer cells).
Fig. 2. The sequence of haematopoietic stem cell transplantation (HSCT) in haematopoietic 
malignancies. Once haematopoietic stem cell transplantation is clinically indicated, stem cells are 
mobilised from their marrow niche using medical mobilising agents in either the patient (autologous) or 
a suitable donor (allogenic). Haematopoietic stem and progenitor cells are harvested, most commonly 
by apheresis. The conditioning phase encompasses treatment with high-dose chemotherapeutic agents 
and/or total body irradiation with the aim of achieving myeloablation.This is followed by infusion of 
the donor stem cells. The aplastic phase in which patients do not have a functional haematopietic system 
lasts between 10 and 20 days during which they are nursed in protective isolation until engraftment is 
achieved. Thus the desired outcome is a patient with a fully functioning haematopoietic system without 
the initial pathology).
S50       August 2019, Vol. 109, No. 8 (Suppl 1)
RESEARCH
alleles may be associated more frequently with particular population 
groups, it is the expression of uncommon population-specific alleles 
that further decreases the chances of identifying suitable donors, even 
in international registries.[26]
There are additional challenges in the South African context to 
providing successful HSCT to all patients in need of the treatment. 
HSCTs are predominantly performed in the private medical sector, 
which limits the access to this treatment modality to patients on 
higher-end medical insurance (17% of the SA population[27]) or 
to those who have the financial means. The high cost involved in 
accessing international donors is therefore a limitation, owing to 
the same reason.[28] The past few years have seen an increase in 
government-funded hospitals providing HSCT, but there is at present 
only one academic centre with a fully-fledged HSCT programme 
for allogeneic (including haploidentical) transplantation. Van 
Eyssen et al.[28] assessed the outcomes of 48 state-funded children 
who received allogeneic HSCTs at the Groote Schuur Hospital/
University of Cape Town Private Academic Hospital transplant unit. 
The authors aimed to evaluate the clinical outcomes of allogeneic 
HSCT in order to motivate future allocation of the substantial 
resources required to sustain such a treatment programme in SA. The 
overall survival in children treated for non-oncological diseases was 
91% (median follow-up of 3.94 years) and 57% (median follow-up 
of 1.86 years) for children treated for haematological malignancies. 
These observations were comparable to outcomes reported in high-
income counterpart facilities,[28] and justify allocating the country’s 
limited resources to additional state-funded programmes.
Towards the aim of facilitating more equitable access to this 
treatment option, the South African Bone Marrow Registry 
(SABMR),[29] an internationally recognised non-profit organisation 
endeavouring to find suitable donors for critically ill children and 
adults in SA, had as of 2017 recruited more than 73 000 registered 
Table 2. Recommended criteria for suitability for haematopoietic stem cell transplantation
Parameter Recommendation
General parameters
Maximum age 75 years
Karnofsky performance index ≥60 - 70
Left ventricular ejection fraction ≥45%
Heart rhythm No uncontrolled arrhythmias
Secondary malignancy None evident
Pregnancy tests Negative
Uncontrolled infections Not evident
Lung function
FEV1/FVC ratio ≥60%
Diffusion capacity ≥50%
Liver function
Serum bilirubin ≤34 μmol/L
ALT/AST ≤2 × normal
Viral hepatitis screen
Negative Preferred
Positive Not an absolute contraindication, but patients with a positive screen may 
risk viral reactivation following a HSCT
HIV screen
Negative Preferred
Positive HIV-positive patients with a CD4 count >100/μL
A low to undetectable viral load, <10 000 copies/mL
HCT-CI Recommended score of 0 - 2
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HCT-CI = haematopoietic cell transplantation-specific comorbidity index.
Adapted from Hamadani et al.[17]
Table 3. Criteria that characterise ‘proven’ and ‘predicted’ poor autologous CD34+ cell mobilisation
Proven poor mobilisers Predicted poor mobilisers
Circulating CD34+ cell peak <20/μL for up to 6 days after mobilisation 
with G-CSF alone
Previous failed collection attempts
Circulating CD34+ cell peak <20/μL up to 20 days after G-CSF in 
combination with chemotherapy
Prior treatment with chemotherapeutic or radiation regimens that 
affect HSPC mobilisation
A yield <2.0 × 106 CD34+ cells/kg after 3 apheresis collections
Two of the following criteria:
• advanced disease treated with >2 lines of chemotherapy
• refractory disease
• extensive bone marrow infiltration
• bone marrow cellularity <30% at the time of mobilisation
• age >65 years
G-CSF = granulocyte colony-stimulating factors; HSPC = haematopoietic stem and progenitor cells.
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donors. The SABMR provides services to patients both locally and 
internationally. Their collaboration with the World Marrow Donor 
Association (WMDA) provides further access for patients to a database 
of over 32 million international donors. The SABMR is coordinating 
a drive to sign on more local donors in order to meet the complex 
requirements of SA’s genetically highly diverse population more 
comprehensively.[26] The Sunflower Fund[30] is an independent not-for-
profit organisation founded as a donor recruitment centre and registry. 
It is actively involved in the education of the population to raise 
awareness regarding the need for South African donors, and assists in 
acquiring funds for patients unable to afford the costs of the HSCT. It 
has created collaborations with international stem cell/bone marrow 
registries, including those of other African countries, such as Ghana.
In the past decade, the use of haploidentical donors has become a 
well-recognised and successful practice should a sibling or matched 
unrelated donor not be unavailable.[31] For African and mixed-race 
patients, a matched unrelated donor is particularly difficult to source 
on any donor registry. This is due to ethnic diversity and unique 
genetic determinants making the likelihood of an international 
donor match unlikely. Additionally, there is a dearth of local 
volunteer donors in these population groups. The pool of suitable 
donors may be further restricted owing to the high prevalence of the 
human immunodeficiency virus (HIV) in the SA population (13.1% 
according to StatsSA).[32] A haploidentical donor from consenting 
first- or second-degree relatives is available immediately, and is 
considerably less costly to procure.
Conditioning
Preparative or conditioning regimens in haematological malignancies 
aim to achieve three goals: (i) to reduce tumour load (treat the 
underlying condition); (ii) to facilitate sufficient immunoablation 
to prepare a niche for new marrow formation; and (iii) to suppress 
immune function sufficiently to prevent graft rejection and graft-
versus-host disease. Conditioning is specifically tailored to each 
pathology and is administered either prior to or after mobilisation 
as well as post HSPC collection. Regimens involve combinations 
of multiple chemotherapeutic agents, total body irradiation 
(TBI), corticosteroids and other disease-specific pharmaceuticals. 
Conventional conditioning regimens range from myeloablative to 
non-myeloablative, based on the dose of chemotherapy and/or TBI.[33] 
The latter encompass myeloablative and antineoplastic alkylating 
agents such as melphalan, busulphan and cyclophosphamide, as 
monotherapy or in various combinations. For example, busulphan-
containing agents or fludarabine (a purine antimetabolite) may be used 
in combination with cyclophosphamide to reduce cyclophosphamide-
specific cellular toxicity.[34,35] The development of reduced-intensity 
conditioning (RIC) regimens with diminished adverse chemotoxicity 
while promoting immunomodulation has improved certain patient 
outcomes, particularly in the elderly.[36,37] The choice to employ a 
specific regimen is based on the balance between immunosuppressive 
and myelosuppressive properties and the desired outcome in the 
management of the specific pathology. For instance, a combination 
of cyclophosphamide and 12 Gy TBI used in myeloablative regimens 
is highly myeloablative and immunosuppressive. Reduction of the 
TBI to 5.5 Gy would be classified as a reduced intensity regimen. 
Fludarabine, cyclophosphamide and 2 Gy TBI may be used in 
non-myeloablative regimens for their immunosuppressive effects.[38] 
Myeloablative protocols have increased toxicity profiles and rely less 
on the graft-versus-malignancy (GVM) effect to eliminate residual 
disease. The reduced-intensity and non-myeloablative regimens are 
less toxic and rely more on the GVM effect to eradicate residual 
disease while reducing graft-versus-host interactions.[38]
Engraftment
An infusion of 2 × 106 harvested CD34+ cells/kg is considered 
the minimum number of transplanted HSPCs needed to reliably 
ensure sustained engraftment.[15] Engraftment success is monitored 
by neutrophil and platelet counts measured daily post transplant. 
Successful neutrophil engraftment is defined as an absolute neutrophil 
count of more than 0.5 × 109 neutrophils/L for 3 consecutive days. 
Platelet engraftment success is attained when the non-transfusion-
related platelet count is more than 20 × 109 platelets/L for 3 
consecutive days.[39] Consensus in the literature considers the number 
of viable CD34+ cells transplanted to be the primary indicator of 
engraftment success or failure, with higher numbers being associated 
with a more favourable prognosis.
Graft-versus-host disease
Graft-versus-host disease (GVHD) is defined as a syndrome in 
which immunocompetent donor immune cells react to and destroy 
host tissues in immunocompromised recipients.[40] Lazaryan 
et al.[41] investigated potential risk factors and found that mobilised 
peripheral blood as a graft source was associated with a higher 
incidence of GVHD. Advanced recipient age was associated with 
a higher incidence of acute and chronic GVHD. Furthermore, 
conditioning regimen intensity appears to have an influence, with 
non-myeloablative conditioning regimens increasing the risk for 
acute GVHD.[41] GVHD is initiated by tissue damage induced 
by the chemotherapeutic regimen prior to the transplant, and is 
intensified as T cell activation and clonal proliferation orchestrate 
cytokines, chemokines and direct cellular toxicity in an exaggerated 
imflammatory reaction.[42] Damage-associated molecular patterns 
(DAMPs) lead to the activation of host antigen presenting cells 
(APCs). The activated APCs subsequently present host antigens 
to the donor’s T cells, resulting in the release of pro-inflammatory 
cytokines that include tumour necrosis factor-a, g-interferon and 
interleukin (IL)-1 and IL-12, which exacerbate tissue damage.[43]
Acute GVHD presents during the treatment phase with 
involvement of the skin, liver and gastrointestinal tract. Diverse 
clinical presentations include exfoliative and/or ulcerative dermatitis, 
liver dysfunction, and severe vomiting and diarrhoea.[44] The 
mechanisms involved in the pathophysiology of chronic GVHD 
remain unclear.[45] Cells and cytokines associated with chronic 
GVHD include CD4+ T cells, CD8+ T cells and IL-1/6/10.[46] 
Chronic GVHD may develop without a history of, or clinically 
diagnosed, acute GVHD.[45] Onset of chronic GVHD occurs roughly 
100 days post transplantation, and involves the skin, mucous 
membranes including the vulva and/or vagina and mouth, liver, 
kidneys, heart and eyes. Symptoms and signs may include erythema, 
dermal and subcutaneous sclerosis, oedema, cytopenia, nephrotic 
syndrome, liver dysfunction, exocrine pancreatic insufficiency and 
cardiomyopathy.[44]
First-line treatment for acute GVHD includes corticosteroids 
either as monotherapy or in combination with other agents such as 
cyclosporine, with the starting dose being dependent on the clinical 
severity.[47] Second-line treatments for steroid-refractory chronic 
GVHD may include extracorporeal photopheresis (ECP) or immune 
modulators such as methotrexate, rituximab and mycophenolate 
mofetil.[47] Serotherapy encompasses antibodies that target T cells 
and other immune cells that would theoretically modulate GVHD 
intensity. Agents such as antithymocyte globulin and alemtuzumab, 
a monoclonal antibody to CD52, have shown promise in prophylaxis 
and/or treatment of this complication, but absence of unequivocal 
long-term benefits, a lack of consensus on treatment regimens and 
their own unwanted effects render these treatments of little benefit 
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in steroid-refractory GVHD currently.[47] Alemtuzumab effectively 
reduces the frequency and severity of GVHD owing to its capacity 
to deplete competent donor T cells, and can be used as GVHD 
prophylaxis.[48] Most SA centres employ this GVHD preventive 
agent. Immune-suppressing drugs such as tacrolimus, sirolimus, 
cyclophosphamide, methotrexate and mycophenolate mofetil may 
also be used in prophylaxis regimens.
A desirable phenomenon known as the GVM effect, may occur as 
donor T cells recognise and destroy residual malignant cells within 
the recipient. GVM is observed in allogeneic HSCT.[49] A potential 
strategy to utilise this effect therapeutically may be through the 
use of T-regulatory cells (Tregs; also known as T-suppressor cells). 
Tregs develop in the thymus and function as important immune 
modulators of self-tolerance.[50] Patients infused with Tregs have 
a lower risk of developing GVHD.[51,52] Infusions of mesenchymal 
stromal cells, found in various tissues including the bone marrow, 
have also been used successfully to reduce the occurrence of 
GVHD.[53,54] These treatments are still experimental and more 
research is needed to define their physiological mechanisms and 
respective actions.
Transplant-related infections
Transplantation-related microbial infections are a leading cause of 
morbidity and mortality post HSCT. Infections may be bacterial, 
viral and/or fungal and may vary between patients. Allogeneic HSCT 
patients should ideally undergo a pre-transplantation assessment of 
IgG antibodies to syphylis, toxoplasmosis and specific viral diseases 
to identify the potential risk of disease re-activation. Syphilis, 
tuberculosis, Toxoplasma gondii and hepatitis B and C viruses 
may persist for life after primary infection and can be reactivated 
post HSCT.[55] Viral infection post HSCT is commonly caused by 
cytomegalovirus, and less commonly by human herpes virus-6, 
parainfluenza virus, varicella zoster virus, respiratory syncytial 
virus and herpes simplex virus. Viral prophylaxis post HSCT may 
include aciclovir, valacyclovir or valganciclovir. Of these, aciclovir is 
used most frequently.[56] Invasive fungal infections include Candida, 
Aspergillus, Mucorales and Pneumocystis jirovecii. Fluconazole, 
voriconazole or posaconazole may be prescribed as prophylaxis. The 
prophylaxis for P. jirovecii includes trimethoprim-sulfamethoxazole, 
dapsone or atovaquone.[56] HIV is not a contraindication for HSCT 
and antiretroviral therapy may be continued post-transplantation if the 
toxcitity permits.[55] Bacteraemias are caused by Gram-positive bacteria 
(such as coagulase-negative Staphylococci, Enterococci) and Gram-
negative organisms such as Pseudomonas aeruginosa.[56] Antibiotic 
prophylaxis, as with ciprofloxacin, has been demonstrated to 
effectively reduce the incidence of Gram-negative sepsis, provided 
the microbiological resistance profile is favourable.[55]
New frontiers in allogeneic 
transplantation
The emergence of RIC regimens has moved the upper age limit of 
myeloablative transplantation well past the 55-year cut-off formerly 
used for myeloablative regimens. Likewise, the barrier to performing 
haploidentical transplantation has been removed by utilising post-
transplant cyclophosphamide to prevent graft failure and graft-
versus-host disease.[57] Two South African challenges in providing 
HSCTs are the high incidence of HIV in potential donors, as well as 
the genetic diversity of the population, which reduces the probability 
of finding a matched unrelated donor in local or international 
registries. Over the past 3 years, haploidentical HSCT has been 
successfully implemented in South African centres for patients with 
no recourse to fully matched sibling or volunteer donors.
Conclusion
With the increasing need for HSCT, it remains a challenge to 
establish and adequately staff HSCT programmes, particularly in 
the state healthcare setting in SA. This leads to implicit rationing 
of healthcare, whereby only patients in proximity to, or referred to 
HSCT centres, have access to this life-changing medical procedure. 
With improved treatment algorithms and increased survival rates 
following HSCT, there will be an additional need for infrastructure 
and skills required for long-term follow-up programmes post 
HSCT.[58] It is essential that all these factors are considered in policy 
making and planning to ensure ethical and equitable allocation of 
resources. Key objectives to achieve public-private parity of HSCT 
services include an increase in the number of clinical haematologist 
training posts and government support for establishment of fully 
resourced HSCT centres in every province. This task will also 
include raising the profile of HSCT in SA by advocacy based 
on haematological treatment successes as well as the creation of 
sustainable pathways to care. These endeavours will be advanced 
by the establishment of a national reporting body to determine the 
number of HSCTs performed in SA on a yearly basis. The data, 
however, would not provide an accurate representation on the 
definitive need of our population, as they would be biased toward 
patients with access to existing stem cell services and would be 
affected by demographic and financial constraints. Challenges in 
the diagnosis and reporting of pathologies, particularly in rural 
and resource-poor communities, will need to be addressed. To 
mitigate the population-specific genetic variability present in 
HLA-genes, recruitment of donors especially from African and 
mixed-race population groups is encouraged by the SABMR. 
However, the prevalence of HIV, and the high migration rate in 
SA make acquiring volunteer donors challenging. Haploidentical 
transplantation is a necessary tool that has to be implemented by 
every HSCT centre in SA to ensure equitable and affordable access 
to HSCT for all patients, but especially for the ethnic subpopulations 
where other donor pathways are limited. Favourable outcomes have 
been observed with haploidentical transplantation, and this may 
offer a suitable alternative in the absence of fully matched suitable 
donors,. Not-for-profit organisations such as the Sunflower Fund 
aim to recruit 100 000 donors of African ancestry by 2030 as part 
of the Stem Cell Registry Alliance (SCRA), and increase education 
and awareness in our population.
The benefits of HSCT are undeniable as it remains one of the 
only curative options for a variety of haematological pathologies, 
thereby decreasing morbidity and mortality in affected patients. In 
the coming years, we need to examine and improve upon the local 
systems in place regarding HSCT so that we can address the lack of 
access to HSCT in the majority of the population. The ultimate aim 
would be to establish a sustainable and cost-effective model to allow 
all South Africans in need of this intervention to have access to the 
required facilities.
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